Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 27, 2008

PharmAthene Retains GTC’s Manufacturing Services for Protexia

  • GTC Biotherapeutics will continue to conduct process development and clinical manufacturing services for PharmAthene’s Protexia® program. The manufacturing work is planned to conclude in the third quarter.

    Protexia is being developed as a pre- and postexposure therapy for victims of a chemical nerve agent attack. It is a recombinant form of human butyrylcholinesterase (rBChE) produced in the milk of transgenic goats.

  • You’re all set! Thank you for subscribing to GEN Highlights.